跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 2026-10-13AI 评分32

Beam Therapeutics 罕见病基因编辑疗法 I/II 期首批数据提示可纠正突变;Pfizer 将与 Enodia 合作

Beam suggests it can correct mutation; Pfizer to collaborate with Enodia

AI 导读

Beam Therapeutics 公布其罕见病基因编辑疗法 I/II 期试验的初步数据,提示可纠正突变。Pfizer 将与 Enodia 合作。

正文

Beam’s first da­ta on a rare dis­ease gene edit­ing ther­a­py: Beam Ther­a­peu­tics shared ini­tial da­ta from a Phase 1/2 tri­al of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news